Search Results

Here you will find the range of pharmaceutical products that we offer in the UK for immunodeficiency, haemophilia, and other rare and serious diseases.

https://www.cslbehring.co.uk/products/product-range

CSL Behring is a specialty biotherapeutics company that is committed to treating people with rare and serious medical conditions.

https://www.cslbehring.co.uk/products

CSL Behring is a global leader in the plasma protein biotherapies industry. We research, develop, manufacture and market biotherapies, which are used to treat serious and rare conditions.

https://www.cslbehring.co.uk/our-company

CSL Behring is a global specialty biopharmaceutical company which aims to identify, develop and commercialise important, new, biotherapeutic products that help to prevent or treat serious medical conditions.

https://www.cslbehring.co.uk/research-and-development

CSL Behring biotherapies are manufactured in state-of-the-art facilities under stringent, controlled conditions.

https://www.cslbehring.co.uk/products/regulatory-compliance

CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide.

https://www.cslbehring.co.uk/terms-of-use

CSL Behring is committed to support Investigator-Initiated Studies (IIS) that advance medical and scientific knowledge of CSL Behring products and the diseases they are designed to treat.

https://www.cslbehring.co.uk/research-and-development/iis

CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide.

https://www.cslbehring.co.uk/careers/roles-at-csl-behring-uk

CSL Behring is committed to improving the quality of life for people with rare and serious diseases worldwide.

https://www.cslbehring.co.uk/home

Product Name Hizentra 200 mg/ml solution for subcutaneous injection Active Ingredient Human normal immunoglobulin Composition One ml contains:

https://www.cslbehring.co.uk/-/media/cslb-uk/product-information/update-april-2023/product-info---hizentra-inc-pfs-update-april-2023.pdf